Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $25.77 million versus the consensus estimate of $23.1 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.